Overview
Healthcare-associated adenoviral disease refers to infections caused by adenoviruses acquired within healthcare settings, often affecting immunocompromised individuals and those with prolonged hospital stays 1.Diagnosis
Clinical presentation includes respiratory symptoms, conjunctivitis, gastroenteritis, and rash 1.
Diagnostic tests: PCR for viral detection in respiratory secretions, stool, or conjunctival swabs 1.
Grading severity based on clinical symptoms and organ involvement, though specific grading systems are not detailed in provided abstracts 1.Management
Supportive care: hydration, fever management, and symptomatic relief 1.
Antiviral therapy: cidofovir (adult dose: 5 mg/kg IV every 8-12 hours) for severe cases in immunocompromised patients 1.
Isolation and infection control measures to prevent spread 1.Special Populations
Pregnancy: Limited specific guidance; supportive care remains primary 1.
Pediatrics: Similar management principles apply, emphasizing hydration and symptom control 1.
Elderly: Increased vigilance for complications; supportive care tailored to comorbidities 1.
Comorbidities: Focus on managing underlying conditions alongside adenoviral infection 1.Key Recommendations
Implement strict infection control measures to prevent healthcare-associated adenoviral transmission (Evidence: Expert opinion) 1.
Use PCR for definitive diagnosis of adenoviral infections in suspected cases (Evidence: Expert opinion) 1.
Consider cidofovir for severe cases in immunocompromised patients, dosed at 5 mg/kg IV every 8-12 hours (Evidence: Expert opinion) 1.References
1 Smith CS, Hailey D, Drummond M. The role of economic appraisal in health technology assessment: the Australian case. Social science & medicine (1982) 1994. link90067-1)